Table 1.
Clinical information of the 10 treatment‐naïve patients who donated samples for this study
| Patient number | Sample date | Age at diagnosis | Sex | BMPCS % | Date BMPCS% | IgG | IgA | IgM | Light chain isotype (kappa/lambda) | Kappa SFLC | Lambda SFLC | Ratio SFLC | M band g/L |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 6/2/15 | 68 | M | 16.2 | 11/29/11 | 20.80 | 0.80 | 0.62 | IgG kappa | 487.50 | 11.20 | 43.53 | 14 g/L |
| 2 | 6/29/15 | 75 | F | 9.6 | 8/29/11 | 22.20 | 1.04 | 0.77 | IgG kappa | No light chains noted | No light chains noted | No light chains noted | Two M bands 3.7 g/L and 8.0 g/L noted, both IgG kappa |
| 3 | 7/7/15 | 70 | F | 26.8 | 2/20/13 | 32.22 | 1.08 | 1.42 | IgG kappa | 890.00 | 9.09 | 97.91 | 29 g/L |
| 4 | 5/25/15 | 61 | M | 11.4 | 3/21/14 | 27.60 | 3.13 | 0.35 | IgG kappa | 29.30 | 21.10 | 1.39 | 16 g/L |
| 5 | 8/12/15 | 73 | M | 16.4 | 4/30/13 | 4.42 | 11.60 | 0.30 | IgA lambda | Testing not done | Testing not done | Not done 13 g/L | |
| 6 | 8/24/15 | 70 | M | 37.4 | 7/19/11 | 2.32 | 32.60 | 0.06 | IgA kappa | Not present | Not present | Not present | 19 g/L |
| 7 | 9/8/15 | 66 | F | 29.8 | 8/20/15 | 4.28 | 16.60 | 0.19 | IgA kappa | 21.58 | 1.63 | 13.24 | 12 g/L |
| 8 | 9/16/15 | 65 | F | 1.6 | 6/3/15 | 18.00 | 1.74 | 0.76 | IgG kappa | 143.04 | 4.43 | 32.29 | 10 g/L |
| 9 | 9/22/15 | 76 | M | 68.0 | 7/31/15 | 2.96 | 0.08 | <0.04 | IgD lambda | Testing not done | Testing not done | Not done 11 g/L | |
| 10 | 6/3/15 | 56 | F | 8.2 | 4/15/13 | 29.50 | 0.25 | 0.46 | IgG lambda | <2.70 | 11.70 | 0.23 | 25 g/L |
Diagnosis: 1, IgG kappa smouldering multiple myeloma; 2, smouldering multiple myeloma; 3, smouldering multiple myeloma; 4, smouldering multiple myeloma; 5, smouldering multiple myeloma; 6, IgA kappa smouldering multiple myeloma; 7, multiple myeloma; 8, multiple myeloma; 9, ISS‐I multiple myeloma; 10, smouldering multiple myeloma.